中化新网讯 上周(1月12日至16日)，化工指数与石油指数各有涨跌。 化工板块方面，化工原料指数累计上涨1.10%、化工机械指数累计上涨2.87%、化学制药指数累计下跌 1.41%、农药化肥指数累计上涨2.99%；石油板块方面，石油加工指数累计下跌3.66%、石油开采指数累 计下跌0.36%、石油贸易指数累计上涨4.17%。 从现货市场看，涨幅前五名的石化产品分别为液氯上涨92.93%、工业级碳酸锂上涨25.75%、环氧丙烷 上涨8.84%、电池级碳酸锂上涨6.73%、POP类聚醚上涨6.10%；跌幅前五名的石化产品分别为维生素D3 下跌4.17%、丙烯酸甲酯下跌3.92%、硝酸下跌2.51%、己内酰胺下跌2.14%、乙烯下跌1.69%。 从现货市场看，涨幅前五名的上市化企分别为博菲电气上涨61.06%、七彩化学上涨27.94%、阿拉丁上 涨20.24%、和顺科技上涨18.62%、渤海化学上涨15.54%；跌幅前五名的上市化企分别为再升科技下跌 26.65%、ST嘉澳下跌18.42%、普利特下跌17.28%、龙高股份下跌14.21%、仁智股份下跌12.54%。 上周，国际原油价格先升后降。截至1月16日，纽约 ...

Group 1 - East Asia Pharmaceutical Co., Ltd. experienced a stock price increase of 5.15%, reaching 21.45 CNY per share, with a trading volume of 48.87 million CNY and a turnover rate of 2.09%, resulting in a total market capitalization of 2.461 billion CNY [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The main revenue composition of East Asia Pharmaceutical includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional (supplementary) products (4.46%) [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares, with an estimated floating profit of approximately 852,300 CNY [2] - The Noan Multi-Strategy Mixed A fund was established on August 9, 2011, with a latest scale of 1.855 billion CNY, achieving a year-to-date return of 8.15% and a one-year return of 79.8% [2] - The fund manager, Kong Xianzheng, has a tenure of 5 years and 57 days, with the fund's total asset size at 5.608 billion CNY, achieving a best return of 101.07% and a worst return of -16.74% during his tenure [3]

（文章来源：每日经济新闻） 科创创新药ETF国泰（589720）跟踪的是科创新药指数（950161），单日涨跌幅限制达20%，该指数从 科技创新领域选取专注于新药研发的上市公司证券作为指数样本，主要覆盖生物医药、化学制药等行业 中致力于创新药物研究与开发的企业，以反映中国医药行业创新发展的整体趋势与市场表现。 华鑫证券指出，2025年是中国创新药出海具有标志性意义的一年，全年BD出海授权交易总金额达到 1356.55亿美元，交易数量达157起，均创历史新高。进入2026年，中国创新出海迎来开门红，持续落地 的BD交易验证了中国创新药的全球竞争力。展望2026年，创新仍是医药行业投资的主线。具体来看， 小核酸药物领域正吸引更多头部企业关注，其在新靶点开发和治疗方便性上的飞跃以及持续验证的临床 数据，使得该领域的对外授权和并购合作也在加速。同时，在GLP-1领域，国内产品市场正形成新价格 体系，但鉴于减重和糖尿病巨大的患者人群，其长期市场空间仍值得期待。此外，口服自免药物的开发 受到重视，国内企业也在探索相关新靶点。 ...

资金面上看，黔源电力近5日主力资金总体呈净流入状态，累计净流入3784.93万元，其中，上一交易日 主力资金全天净流入888.55万元。 黔源电力股价出现异动，截至今日9时51分，股价下跌5.44%，成交513.62万股，成交金额9691.34万 元，换手率为1.20%，公司发布的最新业绩预告显示，预计2025年实现净利润5.67亿元—6.33亿元，净 利润同比增长160.00%—190.00%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有中熔电气、 芯碁微装、誉衡药业等，股价分别上涨20.00%、13.35%、10.03%，股价跌幅较大的有粤桂股份、南侨 食品、中孚实业等，分别下跌6.45%、6.14%、6.01%。 融资融券数据显示，该股最新（1月20日）两融余额3.11亿元，其中，融资余额为3.11亿元，近5日融资 余额合计增加406.64万元，增幅为1.33%。（数据宝） ...

金房能源股价出现异动，截至今日9时39分，股价大涨5.12%，成交91.72万股，成交金额2012.10万元， 换手率为0.96%，公司发布的最新业绩预告显示，预计2025年实现净利润1.09亿元—1.43亿元，净利润 同比增长123.87%—193.70%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有中熔电气、 芯碁微装、誉衡药业等，股价分别上涨20.00%、11.56%、10.03%。 资金面上看，金房能源近5日主力资金总体呈净流入状态，累计净流入997.18万元，其中，上一交易日 主力资金全天净流出7.96万元。（数据宝） （文章来源：证券时报网） ...

Group 1: Macroeconomic Insights - In 2025, China's GDP reached 140.2 trillion yuan, with a nominal growth of 5% year-on-year, surpassing global averages and achieving significant milestones during the "14th Five-Year Plan" [4][5][12] - The economic growth rate showed a pattern of high growth in the first half of the year, with quarterly GDP growth rates of 5.4%, 5.2%, 4.8%, and 4.5% respectively [4][5] - The contribution of net exports to economic growth was 32.7%, indicating strong external demand despite trade tensions [5][12] Group 2: Consumption Trends - Retail sales of consumer goods increased by 3.7% year-on-year, with final consumption contributing approximately 52% to economic growth [6][7] - The "trade-in" policy significantly boosted sales in various categories, with retail sales of home appliances and audio-visual equipment rising by 11% and furniture by 14.6% [6][7] - Service consumption grew rapidly, with a 5.5% increase in service retail sales, highlighting a shift towards experiential and health-related spending [7][8] Group 3: Investment Dynamics - Fixed asset investment in 2025 was 48.5 trillion yuan, a decrease of 3.8% year-on-year, with infrastructure investment down by 2.2% and manufacturing investment up by 0.6% [9][10] - High-tech industry investment saw significant growth, with information services up by 28.4% and aerospace manufacturing by 16.9% [11] - The government plans to increase central budget investment in 2026, which is expected to support overall investment recovery [10][11] Group 4: Trade and Export Performance - In 2025, China's total foreign trade reached 45.47 trillion yuan, with exports growing by 6.1% to 26.99 trillion yuan, marking a historical high [12][13] - The structure of exports has shifted towards high-value-added products, with mechanical and electrical products accounting for 61% of total exports [13][14] - Trade dependency on the U.S. has decreased, with exports to the U.S. dropping to 11.1% of total exports in 2025 [14] Group 5: Automotive Industry Developments - The automotive sector saw a weekly increase in stock performance, with the automotive index rising by 0.5% [15][16] - The introduction of the "price commitment" mechanism for electric vehicles is expected to stabilize sales in Europe and promote high-end and localized production [16][18] - Several provinces have opened channels for 2026 vehicle replacement subsidies, indicating government support for the automotive market [17][18] Group 6: AI and Pharmaceutical Innovations - The collaboration between NVIDIA and Eli Lilly aims to leverage AI in drug discovery, with a projected investment of up to $1 billion over five years [24] - AI is expected to transform traditional drug development processes, shifting from labor-intensive methods to data-driven approaches [24] - The pharmaceutical sector has shown resilience, with a 7.08% return in early 2026, despite recent adjustments in stock prices [25]

Core Viewpoint - The company is committed to implementing an internationalization strategy and has accelerated its expansion into overseas markets [1] Group 1: International Expansion - The company has successfully exported certain chemical raw materials to EU member countries [1] - The sales model for the EU market combines direct sales and distribution [1]

（编辑 丛可心） 证券日报网讯 1月20日，华邦健康发布公告称，公司预计2025年度归属于上市公司股东的净利润盈利 66，000.00万元-73，000.00万元，上年同期亏损29，898.99万元，比上年同期增长320.74%-344.16%。 ...

Group 1: Financial Performance and Product Impact - The price of 6-APA has decreased by approximately 45% to 180 RMB/kg as of January 19, 2026, positively impacting the gross margin of core products like Tazobactam and Sulbactam, which together account for about 40% of the company's revenue in 2024 [2][3] - The new production process for Tazobactam is expected to lower production costs while enhancing product quality, thus improving market competitiveness [3] Group 2: Market Demand and Product Synergy - Piperacillin, a key β-lactam antibiotic, is crucial for combination formulations that address bacterial resistance, with its demand closely tied to downstream formulations [4] - The market demand for Piperacillin is driven by ongoing clinical needs for anti-infection treatments and the increasing application of combination formulations due to rising antibiotic resistance [4] Group 3: Capacity Expansion and Strategic Planning - The company plans to expand VC (Vinyl Carbonate) production capacity from 8,000 tons/year to 10,000 tons/year, with a long-term goal of 20,000 tons/year, driven by the growing demand in the battery market [5] - The expansion is characterized by low investment and quick response to market needs, minimizing overall risk while maximizing economic benefits [5] Group 4: Innovative Protein Development - The "Weiran Protein" product line focuses on high-protein, high-fiber, and low-residue applications, targeting markets such as artificial meat and health foods [6][7] - The company has established competitive advantages in the synthetic biology protein sector, including proprietary strains and advanced technology, positioning itself as a leader in the market [6][7] - Collaborations with academic institutions and the establishment of the "Weiran New Quality Protein Alliance" aim to drive market education and product innovation [7]

Core Viewpoint - The company reported a revenue growth of 6.58% year-on-year for the first three quarters of 2025, indicating a slowdown in growth rate compared to previous periods [2] Group 1: Revenue and Growth - The company's revenue for the first three quarters of 2025 reached 104 million yuan, reflecting a modest increase in sales volume and revenue compared to the same period last year [2] - The growth rate of 6.58% is significantly lower than previous growth rates, raising questions about the factors contributing to this slowdown [2] Group 2: Product Development and Clinical Trials - As of mid-2025, the company's drug, 康替唑胺片, has been adopted by 580 hospitals nationwide, with 180 hospitals achieving formal access and bulk procurement [2] - The company initiated a Phase II clinical trial in April 2023 for the oral formulation of 康替唑胺片 targeting complex skin and soft tissue infections in patients aged 6 to 17, which is currently ongoing [2] - Additional clinical trials for other drugs, including MRX-4, MRX-8, and MRX-5, are progressing, with MRX-4 receiving NDA acceptance in May 2025 for treating complex skin and soft tissue infections [2]